SPY312.23+1.71 0.55%
DIA258.42+1.11 0.43%
IXIC10,207.63+53.00 0.52%

Akero Therapeutics Expands Phase 2a Trial In NASH To Include Cohort Of Cirrhotic Patients

Benzinga · -